Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
(BUTTER Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing tributyrin, a substance that turns into a helpful fatty acid in the body. It aims to see if it can improve brain function and metabolism in people with Parkinson's disease and normal older adults. If successful, it could lead to further studies on using this fatty acid for health benefits. Sodium butyrate, a similar compound to tributyrin, has shown potential in improving motor and cognitive deficits in Parkinson's disease models.
Do I need to stop my current medications for the trial?
The trial excludes people who regularly use anti-cholinergic, benzodiazepines, or neuroleptic drugs, so you may need to stop these medications to participate. The protocol does not specify about other medications.
What makes the drug Tributyrin unique compared to other treatments?
Tributyrin is unique because it is a triglyceride that can be metabolized into butyrate, a short-chain fatty acid that has potential anti-inflammatory and anticancer properties. This makes it different from other treatments that may not provide the same metabolic benefits or target similar pathways.12345
Who Is on the Research Team?
Nicolaas I Bohnen, MD, PhD
Principal Investigator
University of Michigan
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 500mg TID tributyrin supplement for 30 days +/- 7 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tributyrin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nicolaas Bohnen, MD, PhD
Lead Sponsor